Department of Radiation Oncology, Hokkaido University Hospital, Sapporo, Hokkaido 060-8648, Japan.
Department of Gynecology, Hokkaido University Hospital, Sapporo, Hokkaido 060-8648, Japan.
J Radiat Res. 2023 Mar 23;64(2):463-470. doi: 10.1093/jrr/rrac086.
Most oncogenic human papilloma virus (HPV) genotypes stratify into two species, α-7 HPV and α-9 HPV. There are several studies that evaluate the relationship between HPV species and treatment outcomes and reports that HPV species is prognostic. The HPV genotyping was conducted using biopsy specimens which had been stored in these studies. We conducted the study using the HPV test performed by cytology specimens which is less invasive and more useful in clinical settings. This study enrolled 46 patients who received HPV genotyping before the definitive radiotherapy. The results of the HPV genotyping were classified into HPVα-7, HPVα-9 and negatives. Of the 46 patients, 10 were positive for HPVα-7, 21 positive for HPVα-9 and 15 were negative. The median follow-up period was 38 months (range 4-142). The HPVα-7, HPVα-9 and negative groups showed the 3-year overall survival (OS; 59.3%, 80.4% and 72.2% [P = 0.25]); local control (LC; 67.5%, 81% and 80% [P = 0.78]); pelvic control (PC) (50%, 81% and 72.7% [P = 0.032]); pelvic lymph node (PLN) control (78.7%, 95% and 92.3% [P = 0.012]); distant metastasis free (DMF) survival (50%, 75.4% and 42.8% [P = 0.098]); and progression free survival (PFS) rate of patients (30%, 66.7% and 38.9% [P = 0.085]), respectively. Patients with HPVα-7 showed statistically significant poorer PC than the HPVα-9 group, in multivariate analysis. This result is consistent with previous studies for HPV positive patients. The HPV negativity rate was higher in this study than in other studies and further work on this may be needed for clinical use.
大多数致癌性人类乳头瘤病毒（HPV）基因型可分为两种，α-7 HPV 和 α-9 HPV。有几项研究评估了 HPV 种属与治疗结果之间的关系，并报告 HPV 种属具有预后意义。这些研究中的 HPV 基因分型是使用活检标本进行的，这些标本在这些研究中被储存。我们使用细胞学标本进行 HPV 检测，这种方法具有侵袭性更小，在临床环境中更有用。本研究纳入了 46 例在接受根治性放疗前接受 HPV 基因分型的患者。HPV 基因分型的结果分为 HPVα-7、HPVα-9 和阴性。在这 46 例患者中，HPVα-7 阳性 10 例，HPVα-9 阳性 21 例，阴性 15 例。中位随访时间为 38 个月（范围 4-142）。HPVα-7、HPVα-9 和阴性组患者 3 年总生存率（OS；59.3%、80.4%和 72.2%[P=0.25]）、局部控制率（LC；67.5%、81%和 80%[P=0.78]）、盆腔控制率（PC；50%、81%和 72.7%[P=0.032]）、盆腔淋巴结（PLN）控制率（78.7%、95%和 92.3%[P=0.012]）、无远处转移生存率（DMF；50%、75.4%和 42.8%[P=0.098]）和疾病无进展生存率（PFS；30%、66.7%和 38.9%[P=0.085]）。多因素分析显示，HPVα-7 阳性患者的 PC 明显差于 HPVα-9 阳性患者。这一结果与以前针对 HPV 阳性患者的研究一致。本研究中 HPV 阴性率高于其他研究，可能需要进一步研究，以便为临床应用提供依据。
